IM Cannabis Corp

IM Cannabis Corp. engages in the production and sale of medical cannabis products. It offers dry flower products and cannabis oil products under the IMC brand. The company was founded on March 7, 1980 and is headquartered in Glil Yam, Israel.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / May 4, 2021 / IM Cannabis Corp. ("IMC" or the "Company") (CSE:IMCC)(NASDAQ:IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational cannabis sector with operations in Israel, Germany and Canada, announces that it has commenced an overnight marketed offering (the "Offering") of the Company's common shares (each an "Offered Share") on a best-efforts agency basis. The Company may also issue to purchasers of Offered Shares, for no additional consideration, common share purchase warrants (each a "Warrant") that would entitle the holder to purchase common shares of the Company at a price and for a term to be determined in the context of marketing for the Offering.

IM Cannabis Announces Proposed Public Offering of Securities

With Israel 's Fast-Paced E-Commerce Adoption and Cannabis Market's High Growth Rate (Averaging 4 Percent 1 per Month), Panaxia's Online Platform to Support Patient Base Expansion Acquisition Broadens IMC's Patient Offering in Israel, Facilitates Stronger Direct Patient Relationships and Enables the Company to Grow its IMC Brand Awareness Offers Additional Opportunity to Generate Revenue and Margin on Third-Party Products and is Synergistic with IMC's Premium and Super-Premium Canadian Indoor Production Portfolio Adds Key Storage, Distribution and Delivery Capabilities, Plus Established Call Center to Support Growth as Israeli Market Prepares for Potential Adult-Use Recreational Cannabis Legalization TORONTO, ON / GLIL YAM and LOD, ISRAEL /  April 30, 2021 / IM Cannabis Corp. ("IMC" or the "Company") (CSE:IMCC)(NASDAQ:IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational cannabis sectors with operations in Israel, Germany and Canada, announced today that its fully owned Israeli subsidiary, IMC Holdings Ltd., along with Panaxia Pharmaceutical Industries Israel Ltd.

IM Cannabis Acquires Israel's Largest Retail and Online Pharmacy Business from Panaxia, Creating a Vertically Integrated Global Platform for the IMC Brand

Q4 2020: revenues of $4.9 million and gross margin of 57%1; FY 2020: revenues of $15.9 million and gross margin of 55% 1 . Preliminary unaudited Q1 2021 revenues expected to be in the range of $8.5 - $9.0 million; gross margin expected to be in the range of 50% to 55%.

IM Cannabis Reports Fiscal 2020 Results; Provides Preliminary Q1 Results and Q2 Outlook

Multi-country medical and recreational cannabis operator IM Cannabis (CSE:IMCC) (NASDAQ:IMCC) is gearing up to expand its product offering in the German market this year with a range of specially formulated high-THC, balanced-THC and CBD oil extracts. The company announced its German subsidiary, Adjupharm GmbH, signed a two-year supply agreement with MediPharm Labs (OTC:MEDIF) for the production and delivery of IMC-branded, specially formulated extracts.

IM Cannabis, MediPharm Labs Sign Supply Agreement For German Market

TORONTO, ON and BAD OLDESLOE, GERMANY and GLIL YAM, ISRAEL / ACCESSWIRE / April 13, 2021 / IM Cannabis Corp. ("IMC" or the "Company") (CSE:IMCC)(NASDAQ:IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational cannabis sector with operations in Canada, Israel and Germany, announced that its subsidiary, Adjupharm GmbH ("Adjupharm"), recently signed a supply agreement (the "Supply Agreement") with MediPharm Labs Australia Pty Ltd, a subsidiary of MediPharm Labs Corp. ("MediPharm Labs") (TSX:LABS), (OTCQX:MEDIF), (FSE:MLZ), a global leader in specialized, research-driven, pharmaceutical-quality cannabis extraction, distillation and derivative products. The initial term of the Supply Agreement is two years, with a two-year automatic extension period.

Adjupharm Signs Supply Agreement with MediPharm Labs, Paving Way for IM Cannabis-Branded Extracts Launch in German Market

Multi-country medical and recreational cannabis operator, IM Cannabis (CSE:IMCC) (NASDAQ:IMCC) continues to strategically expand in Canada with its second acquisition of 2021. The company announced this week it reached a definitive agreement to acquire MYM Nutraceuticals and its Licensed Producer subsidiary Highland Growth.

Israel-Based IM Cannabis Continues Canadian Expansion With $67.6M MYM Nutraceuticals Acquisition

Highland Grow is currently profitable on an EBITDA basis and the Transaction is expected to be immediately accretive to IMC Highland Grow is expected to generate net revenue of $29 million and $38 million and gross margins of 34% to 36% in 2021 and 2022, respectively[1] Purchase price implies 2.3x net revenue and 6.7x EBITDA in 2022 with synergies MYM shareholders will receive 0.022 IMC shares for each MYM share, representing a price of $0.195 based on respective closing prices on March 31, 2021 Super premium positioning, complementary brands, enhanced distribution and export opportunities to Israel and European markets TORONTO, ON, VANCOUVER, BC, and GLIL YAM, ISRAEL / ACCESSWIRE / April 1, 2021 / IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational cannabis sector with operations in Israel, Germany and Canada is pleased to announce that it has entered into a definitive agreement (the "Arrangement Agreement") to acquire MYM Nutraceuticals Inc. ("MYM") and its licensed producer subsidiary Highland Grow Inc. ("Highland Grow"), pursuant to a plan of arrangement to be completed under the Business Corporations Act (British Columbia) (the "Transaction"). The Transaction reinforces the Company's strategy as a leading global premium cannabis producer and purveyor.

IM Cannabis to Acquire MYM Nutraceuticals and Its Licensed Producer Subsidiary, Highland Grow

TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / March 31, 2021 / IM Cannabis Corp. (the "Company" or "IMC") (CSE:IMCC)( NASDAQ:IMCC), a multi-country operator ("MCO") in the medical cannabis sector with operations in Israel, Germany and Canada, is pleased to announce that it has filed a final short form base shelf prospectus (the "Shelf Prospectus") with the securities commissions or similar securities regulatory authorities in each of the provinces and territories of Canada and a corresponding shelf registration statement on Form F-10 (the "Registration Statement") with the United States Securities and Exchange Commission (the "SEC") under the Multijurisdictional Disclosure System established between Canada and the United States. The Shelf Prospectus and Registration Statement, when declared effective, will allow the Company to offer up to an aggregate of US$250,000,000 (or its equivalent in other currencies) of common shares, warrants, subscription receipts, debt securities, units (collectively, the "Securities"), or any combination of such Securities from time to time, during the 25-month period that the Shelf Prospectus remains effective.

IMC Announces Filing of Final Short Form Base Shelf Prospectus

Akerna Corp

Trulieve Cannabis Corp.

Benzinga's Cannabis Insider is a live daily show for cannabis investors. On Monday's show, hosts Patrick Lane and Javier Hasse discussed recent news about MAZAKALI and Satori Investment Partners' new $20 million cannabis fund, as well as the following publicly-traded companies:

Video: Benzinga Cannabis Insider 3/22 Ft. IM Cannabis, Cresco Labs, Akerna, Trulieve, And More

Oren Shuster is CEO of IM Cannabis, a Nasdaq-listed company focused on legal global markets. Recently closed deal with Trichome Financial; Israeli, European and Canadian cannabis markets different from the US.

IM Cannabis Corporation, Oren Shuster (Video)

TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / March 18, 2021 / IM Cannabis Corp. (the "Company" or "IMC") (CSE:IMCC), (NASDAQ:IMCC), a multi-country operator ("MCO") in the medical cannabis sector with operations in Israel, Germany and Canada, is pleased to announce the closing of its acquisition of Trichome Financial Corp. ("Trichome"), previously announced on December 30, 2020 (the "Transaction"). The Transaction was completed pursuant a plan of arrangement under the Business Corporations Act (Ontario).

IMC Closes Acquisition of Trichome, Establishing Global Growth Platform in Both Adult Use and Medical Cannabis Markets

News for IM Cannabis Corp Stock (IMCC)